DeeperML

Isomorphic Labs, a spinout of Google's DeepMind, has successfully secured $600 million in its first external funding round. The investment, led by Thrive Capital with participation from GV and follow-on capital from existing investor Alphabet, aims to accelerate the company's AI-driven drug design programs and advance therapeutic programs into clinical trials. Isomorphic Labs, founded in 2021 by Sir Demis Hassabis, is focused on developing treatments for millions of patients worldwide by applying AI toward reimagining and accelerating drug discovery, with internal programs primarily focused on oncology and immunology.

The funding will be used to further develop Isomorphic Labs' next-generation AI drug design engine and expand its staff. Their drug discovery portfolio includes small molecule programs being developed with Eli Lilly and Novartis. A key technology is AlphaFold 3, developed jointly with Google DeepMind, which predicts molecular structures with unprecedented precision. CEO Sir Demis Hassabis stated the funding will "turbocharge" their AI drug design engine and advance their programs into clinical development, furthering their mission to solve all disease with AI.


References :

• www.genengnews.com: DeepMind Spinout Isomorphic Labs Raises $600M Toward AI Drug Design
• Crunchbase News: Alphabet-Backed Isomorphic Labs Raises $600M For AI Drug Development
• Maginative: Isomorphic Labs Secures $600M to Accelerate AI-Powered Drug Discovery

Classification:

• HashTags: #AIDrugDesign #IsomorphicLabs #DeepMind
• Company: Isomorphic Labs
• Target: Pharmaceutical Industry
• Product: Drug Discovery
• Feature: AI Drug Design
• Type: AI
• Severity: Informative